Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation

Details

Serval ID
serval:BIB_13F47567F876
Type
Article: article from journal or magazin.
Collection
Publications
Title
Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation
Journal
Fertility and Sterility
Author(s)
Frydman  R., Cornel  C., de Ziegler  D., Taieb  J., Spitz  I. M., Bouchard  P.
ISSN
0015-0282
Publication state
Published
Issued date
11/1991
Peer-reviewed
Oui
Volume
56
Number
5
Pages
923-7
Notes
Journal Article --- Old month value: Nov
Abstract
OBJECTIVE: To report a preliminary study on the efficacy of a gonadotropin-releasing hormone antagonist (Nal-Glu) for preventing premature luteinizing hormone (LH) and progesterone (P) rise in controlled ovarian hyperstimulation using clomiphene citrate (CC) and human menopausal gonadotropin (hMG). DESIGN: Participants in the study formed two groups. Both groups received CC-hMG and Nal-Glu. Group II differs from group I for receiving human chorionic gonadotropin (hCG) and blood samples for 10 days after the second Nal-Glu injection. SETTING: Centre de Fecondation in Vitro, Hopital Antoine Beclere. PATIENTS: Eleven women 25 to 34 years of age and having normal menstrual cycles using barrier method of contraception not attempting pregnancies participated in the study. INTERVENTION: Daily blood samples, pelvic ultrasound, and CC-hMG/Nal-Glu/hCG administration. MAIN OUTCOME MEASURES: (1) Spontaneous LH surge and P rise, follicular growth, and plasma E2 levels in cycles with CC-hMG/Nal-Glu administration and (2) luteal phase after hCG injection in subjects previously treated with CC-hMG/Nal-Glu. RESULTS: Plasma E2 level increased from 983 +/- 80 pg/mL (mean +/- SEM) on the day of the first Nal-Glu administration to 1,159 +/- 102 and 1,610 +/- 114 pg/mL (mean +/- SEM) 24 and 48 hours later. In 10 women, LH and P remained low for at least 96 hours after the first Nal-Glu administration. In one subject, plasma LH was already elevated at the time of the first Nal-Glu injection. In women who received hCG, plasma E2 and P reached a maximum of 1,258 +/- 313 pg/mL and 50.3 +/- 12.8 ng/mL (mean +/- SEM), respectively, on the 6th day of the luteal phase. CONCLUSION: Our results suggest that timely Nal-Glu injections can prevent LH and P rise for at least 96 hours, in spite of increasing levels of plasma E2. Moreover, Nal-Glu had no adverse effect on the kinetic of E2 rise, the follicular growth, or on the post-hCG hormonal profile.
Keywords
Adult Estradiol/blood Female Gonadotropin-Releasing Hormone/*analogs & derivatives/*antagonists & inhibitors/pharmacology Humans Luteinizing Hormone/*blood Menotropins/pharmacology Menstruation/drug effects Ovarian Follicle/anatomy & histology/drug effects Ovarian Hyperstimulation Syndrome/*blood Progesterone/*blood Time Factors
Pubmed
Web of science
Create date
28/02/2008 11:36
Last modification date
20/08/2019 12:42
Usage data